Related Experiment Video
Updated: Apr 18, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Predictors of long-term clinical endpoints in patients with refractory angina
Thomas J Povsic1, Samuel Broderick1, Kevin J Anstrom1
1Duke Clinical Research Institute, Durham, NC (T.J.P., S.B., K.J.A., L.K.S., M.O., E.L.E., P.K.S., J.H.A.).
Insights
Patients with refractory angina (RA) medically managed have modest mortality but high hospitalization rates. Novel therapies are needed to mitigate symptoms and reduce healthcare costs for this patient group.
Area of Science:
- Cardiology
- Clinical Outcomes Research
- Health Economics
Background:
- Refractory angina (RA) clinical outcomes are poorly understood.
- Limited data exists on characteristics influencing endpoints in medically stable RA patients.
Purpose of the Study:
- To characterize clinical endpoints and costs in patients with advanced coronary artery disease (CAD) and refractory angina.
- To identify predictors of mortality and rehospitalization in this population.
Main Methods:
- Retrospective analysis of 1908 patients with advanced CAD ineligible for revascularization from the Duke Database for Cardiovascular Disease (1997-2010).
- Evaluation of 3-year incidence of death, cardiac rehospitalization, and composite endpoints.
- Analysis of predictors for mortality and associated healthcare costs.
Main Results:
- The 3-year incidence of death was 13.0%, cardiac rehospitalization was 43.5%, and a composite endpoint was 52.2%.
- Predictors of mortality included age, low ejection fraction, multivessel CAD, and history of congestive heart failure (CHF).
- Total 3-year rehospitalization costs were $10,185 per patient.
Conclusions:
- Medically managed, stable refractory angina patients experience modest mortality but high rates of hospitalization and resource utilization.
- Findings highlight the need for new therapies to improve symptom control and reduce healthcare burden in RA.
- Further research into novel treatments is warranted to address the significant health care costs associated with refractory angina.
Background:
Clinical outcomes in patients with refractory angina (RA) are poorly characterized and variably described. Using the Duke Database for Cardiovascular Disease (DDCD), we explored characteristics that drive clinical endpoints in patients with class II to IV angina stabilized on medical therapy.
Methods And Results:
We explored clinical endpoints and associated costs of patients who underwent catheterization at Duke University Medical Center from 1997 to 2010 for evaluation of coronary artery disease (CAD) and were found to have advanced CAD ineligible for additional revascularization, and were clinically stable for a minimum of 60 days. Of 77 257 cardiac catheterizations performed, 1908 patients met entry criteria. The 3-year incidence of death; cardiac rehospitalization; and a composite of death, myocardial infarction, stroke, cardiac rehospitalization, and revascularization were 13.0%, 43.5%, and 52.2%, respectively. Predictors of mortality included age, ejection fraction (EF), low body mass index, multivessel CAD, low heart rate, diabetes, diastolic blood pressure, history of coronary artery bypass graft surgery, cigarette smoking, history of congestive heart failure (CHF), and race. Multivessel CAD, EF<45%, and history of CHF increased risk of mortality; angina class and prior revascularization did not. Total rehospitalization costs over a 3-year period per patient were $10 185 (95% CI 8458, 11912) in 2012 US dollars.
Conclusions:
Clinically stable patients with RA who are medically managed have a modest mortality, but a high incidence of hospitalization and resource use over 3 years. These findings point to the need for novel therapies aimed at symptom mitigation in this population and their potential impact on health care utilization and costs.
More Related Videos
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
Related Concept Videos
Angina V: Nursing Management
Angina II: Classification
Angina III: Clinical Manifestations and Assessment
Angina IV: Management
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations